Targeting GNG4 inhibits tumor progression and restores enzalutamide sensitivity in prostate cancer by suppressing autophagy

Key Points

• Tumor progression is inhibited when GNG4 is targeted, restoring sensitivity to enzalutamide.
• Key evidence shows a marked increase in susceptibility to enzalutamide treatment through autophagy suppression.
• Analysis of autophagy pathways clarifies the mechanistic role of GNG4 in prostate cancer progression.
• Supports potential for GNG4 as a therapeutic target in overcoming enzalutamide resistance.